drugset / Trial / NCT05613868
TPN-101 in Aicardi-Goutières Syndrome (AGS)
NaSingle-groupOpen-labelTreatment
Summary
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
Timeline
- Start
- 2023-03-15
- Primary completion
- 2025-02-27
- Completion
- 2025-02-27
Outcome
Outcome not reported
Stopped (Business): “Business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPN-101 | Unknown | 100 mg | — |
| Subject | TPN-101 | Unknown | 400 mg | — |